| BID | 195.00 | ASK | 212.44 | ||
| Open | 199.60 | Previous Close | 200.28 | ||
| Pre-Market | - | After-Market | 199.12 | ||
| - - | - -% |
| Target Price | 228.40 | Analyst Rating | Moderate Buy 2.20 | |
| Potential % | 14.70 | Finscreener Ranking | ★★+ 47.54 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 52.31 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 63.43 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★★+ 41.76 | |
| Market Cap | 17.00B | Earnings Rating | Sell | |
| Price Range Ratio 52W % | 75.05 | Earnings Date | 2nd Aug 2021 |
Today's Price Range 197.54200.39 | 52W Range 146.12216.74 | 5 Year PE Ratio Range 26.6074.50 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.30% | ||
| 1 Month | 5.13% | ||
| 3 Months | 6.34% | ||
| 6 Months | 7.69% | ||
| 1 Year | 30.54% | ||
| 3 Years | 86.53% | ||
| 5 Years | 196.67% | ||
| 10 Years | 540.93% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 9.33 | |||
ROE last 12 Months | 10.59 | |||
ROA (5Y Avg) | 5.00 | |||
ROA last 12 Months | 6.43 | |||
ROC (5Y Avg) | 5.89 | |||
ROC last 12 Months | 8.13 | |||
Return on invested Capital Q | 1.65 | |||
Return on invested Capital Y | 1.65 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 5.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 42.90 | ||||
| 5.10 | ||||
| 6.36 | ||||
| 24.70 | ||||
| -33.40 | ||||
| 8.03 | ||||
| -455.28 | ||||
| 38.94 | ||||
| 21.37B | ||||
| Forward PE | 23.32 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.40 | ||||
| 2.10 | ||||
| 0.31 | ||||
| 0.46 | ||||
| 14.90 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 43.20 | ||||
| 17.90 | ||||
| 24.90 | ||||
| 13.20 | ||||
| 12.79 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.11B | ||||
| 31.18 | ||||
| 6.16 | ||||
| 6.32 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.81 | ||||
| 1.60 | ||||
| 9.07 | ||||
| 9.91 | ||||
| Payout ratio | 30.00 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2021 | 1.80 | 1.63 | -9.44 |
| Q03 2021 | 1.56 | 1.73 | 10.90 |
| Q02 2021 | 1.24 | 1.48 | 19.35 |
| Q01 2021 | 0.97 | 1.31 | 35.05 |
| Q04 2020 | 1.57 | 1.64 | 4.46 |
| Q03 2020 | 1.43 | 1.45 | 1.40 |
| Q02 2020 | 1.26 | 1.32 | 4.76 |
| Q01 2020 | 1.11 | 1.23 | 10.81 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2021 QR | 1.50 | -6.25 | Negative |
| 9/2021 QR | 1.85 | 10.12 | Positive |
| 3/2022 FY | 7.50 | 7.60 | Positive |
| 3/2023 FY | 8.51 | 8.82 | Positive |
| Next Report Date | 2nd Aug 2021 |
| Estimated EPS Next Report | 1.50 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 823.47K |
| Shares Outstanding | 85.38M |
| Trades Count | 12.98K |
| Dollar Volume | 109.03M |
| Avg. Volume | 690.96K |
| Avg. Weekly Volume | 635.14K |
| Avg. Monthly Volume | 935.33K |
| Avg. Quarterly Volume | 752.30K |
STERIS plc (Ireland) (NYSE: STE) stock closed at 199.12 per share at the end of the most recent trading day (a -0.58% change compared to the prior day closing price) with a volume of 849.92K shares and market capitalization of 17.00B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 13000 people. STERIS plc (Ireland) CEO is Walter M. Rosebrough.
The one-year performance of STERIS plc (Ireland) stock is 30.54%, while year-to-date (YTD) performance is 5.05%. STE stock has a five-year performance of 196.67%. Its 52-week range is between 146.12 and 216.74, which gives STE stock a 52-week price range ratio of 75.05%
STERIS plc (Ireland) currently has a PE ratio of 42.90, a price-to-book (PB) ratio of 5.10, a price-to-sale (PS) ratio of 6.36, a price to cashflow ratio of 24.70, a PEG ratio of 2.32, a ROA of 6.43%, a ROC of 8.13% and a ROE of 10.59%. The company’s profit margin is 12.79%, its EBITDA margin is 24.90%, and its revenue ttm is $3.11 Billion , which makes it $31.18 revenue per share.
Of the last four earnings reports from STERIS plc (Ireland), there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.50 for the next earnings report. STERIS plc (Ireland)’s next earnings report date is 02nd Aug 2021.
The consensus rating of Wall Street analysts for STERIS plc (Ireland) is Moderate Buy (2.2), with a target price of $228.4, which is +14.70% compared to the current price. The earnings rating for STERIS plc (Ireland) stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
STERIS plc (Ireland) has a dividend yield of 0.81% with a dividend per share of $1.60 and a payout ratio of 30.00%.
STERIS plc (Ireland) has a Buy technical analysis rating based on Technical Indicators (ADX : 9.43, ATR14 : 3.34, CCI20 : 96.69, Chaikin Money Flow : -0.17, MACD : 0.49, Money Flow Index : 56.43, ROC : 4.15, RSI : 54.61, STOCH (14,3) : 79.57, STOCH RSI : 0.27, UO : 50.32, Williams %R : -20.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of STERIS plc (Ireland) in the last 12-months were: Cary L Majors (Option Excercise at a value of $209 160), Cary L Majors (Sold 7 573 shares of value $1 230 997 ), Daniel A. Carestio (Option Excercise at a value of $2 630 085), Daniel A. Carestio (Sold 36 500 shares of value $6 448 703 ), David B. Lewis (Option Excercise at a value of $49 312), David B. Lewis (Sold 1 560 shares of value $302 312 ), J. Adam Zangerle (Option Excercise at a value of $655 727), J. Adam Zangerle (Sold 14 252 shares of value $2 514 856 ), Jacqueline B. Kosecoff (Option Excercise at a value of $98 655), Jacqueline B. Kosecoff (Sold 3 121 shares of value $601 073 ), Julia K. Madsen (Option Excercise at a value of $299 351), Julia K. Madsen (Sold 4 900 shares of value $992 636 ), Julia Madsen (Option Excercise at a value of $299 351), Julia Madsen (Sold 4 900 shares of value $992 636 ), Karen L. Burton (Option Excercise at a value of $0), Karen L. Burton (Sold 4 602 shares of value $825 682 ), Michael J. Tokich (Option Excercise at a value of $1 498 560), Michael J. Tokich (Sold 28 000 shares of value $5 268 945 ), Richard C. Breeden (Sold 45 000 shares of value $6 904 302 ), Walter M. Rosebrough (Option Excercise at a value of $9 819 226), Walter M. Rosebrough (Sold 142 085 shares of value $22 670 740 )
STERIS plc (Ireland)
Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.
CEO: Walter M. Rosebrough
Telephone: +353 12322000
Address: 70 Sir John Rogerson's Quay, Dublin D02 R296, , IE
Number of employees: 13 000
